We are live on ! Find out more
RVMD icon

Revolution Medicines

184 hedge funds and large institutions have $4.64B invested in Revolution Medicines in 2023 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 81 increasing their positions, 34 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 34

87% more call options, than puts

Call options by funds: $19.1M | Put options by funds: $10.2M

50% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 36

49% more capital invested

Capital invested by funds: $3.11B → $4.64B (+$1.52B)

44% more funds holding in top 10

Funds holding in top 10: 913 (+4)

10% more funds holding

Funds holding: 168184 (+16)

4.28% less ownership

Funds ownership: 102.97%98.68% (-4.3%)

Holders
184
Holders Change
+16
Holders Change %
+9.52%
% of All Funds
2.68%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.19%
New
54
Increased
81
Reduced
34
Closed
36
Calls
$19.1M
Puts
$10.2M
Net Calls
+$8.88M
Net Calls Change
+$5.64M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$427M +$104M +4,309,611 +41%
Vanguard Group
2
Vanguard Group
Pennsylvania
$420M +$120M +4,990,800 +52%
BlackRock
3
BlackRock
New York
$372M +$98.1M +4,082,900 +46%
FCM
4
Farallon Capital Management
California
$193M +$82M +3,411,374 +103%
NI
5
Nextech Invest
Switzerland
$181M +$35M +1,457,211 +30%
State Street
6
State Street
Massachusetts
$179M +$57.3M +2,385,751 +62%
BI
7
BVF Inc
California
$172M +$48.1M +2,000,000 +50%
CC
8
Casdin Capital
New York
$164M +$93.8M +3,904,775 +216%
ACM
9
AH Capital Management
California
$163M +$137M +5,697,067 New
AI
10
Alphabet Inc
California
$152M +$127M +5,301,512 New
BBA
11
Baker Bros. Advisors
New York
$148M +$59M +2,457,164 +91%
BG
12
Bellevue Group
Switzerland
$146M +$8.88M +369,500 +8%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$133M -$11M -458,353 -9%
JP Morgan Chase
14
JP Morgan Chase
New York
$126M +$2.68M +111,710 +3%
BC
15
Boxer Capital
California
$123M -$9.73M -404,800 -9%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$119M +$83.3M +3,465,332 +496%
Morgan Stanley
17
Morgan Stanley
New York
$94.8M +$60.2M +2,504,375 +312%
AVM
18
Arch Venture Management
Illinois
$92.7M +$77.7M +3,233,490 New
DM
19
Deerfield Management
New York
$88.6M +$32.2M +1,338,577 +76%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$85.4M +$21.8M +906,052 +44%
WP
21
Woodline Partners
California
$84.9M -$4.46M -185,405 -6%
Holocene Advisors
22
Holocene Advisors
New York
$82.7M +$16.6M +691,433 +32%
Janus Henderson Group
23
Janus Henderson Group
United Kingdom
$63.1M -$991K -41,259 -2%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$51.5M +$3.21M +133,558 +8%
AG
25
Artal Group
Luxembourg
$48.6M -$20M -833,788 -33%

RVMD Hedge Fund Activity: Q4 2023 in Review

184 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q4 2023, worth a combined $4.64B — up 49% from $3.11B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new RVMD positions and 36 closed out — a net gain of 18 holders — while 81 added to existing stakes and 34 trimmed.

The largest buyer was Alphabet Inc, opening a new position worth an estimated $127M. The largest seller was EcoR1 Capital, cutting an estimated $131M.

  • 184 institutional investors held Revolution Medicines (RVMD) as of Q4 2023, up from 168 in Q3 2023.
  • Funds reported $4.64B of Revolution Medicines stock for Q4 2023, up 49% quarter-over-quarter.
  • 54 funds opened new Revolution Medicines positions in Q4 2023 and 36 closed out, a net change of +18 holders.
  • The largest Revolution Medicines buyer in Q4 2023 was Alphabet Inc, an estimated $127M added.
  • The largest Revolution Medicines seller in Q4 2023 was EcoR1 Capital, an estimated $131M sold.

Based on aggregated 13F filings for Q4 2023.